Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 27, 2010

Jubilant and Endo Broaden Oncology Drug Discovery Partnership

  • Jubilant Biosys and Endo Pharmaceuticals have expanded their year-old oncology drug discovery alliance. The decision follows Jubilant’s achievement of an early-stage milestone.

    The collaboration involves joint target discovery and Jubilant generating and delivering preclinical anticancer candidates to Endo. Jubilant Biosys is a subsidiary of India-based custom research and manufacturing services company Jubilant Organosys. The firm provides drug discovery and development services to the pharma industry worldwide. 

    “This collaboration further reinforces the concept of globally leveraged R&D,” comments Jubilant’s Sri Msur, CEO and president of global drug discovery and development. “This expansion is testimony to Jubilant’s focus on building worldclass oncology capabilities, among other therapeutic areas.”

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »